Form 10-Q Erasca, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Form 10-Q Erasca, Inc. For: Jun 30
August 13, 2024 1:52 PM EDT
Goldman Sachs analyst Chris Shibutani lowered the price target on Erasca Inc (NASDAQ: ERAS) to $3.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "Post the company's prior announcement in May of a strategic reset with subsequent financings, the company's 2Q24 operational and program updates (see... More
August 13, 2024 6:11 AM EDT
H.C. Wainwright analyst Andres Y. Maldonado raised the price target on Erasca Inc (NASDAQ: ERAS) to $6.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "What to expect from the newly initiated SEACRAFT-2 study. Erasca recently announced the initiation of the global SEACRAFT-2 Phase 3 trial to evaluate the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib for patients with NRAS-mutant melanoma. Our positive outlook on this program is... More
